Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1156 to 1170 of 1433 results for primary care

  1. Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

    In development Reference number: GID-TA10555 Expected publication date: TBC

  2. Evidence summaries: process guide (PMG31)

    This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance

  3. Filgotinib for treating moderately to severely active ulcerative colitis (TA792)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.

  4. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.

  5. CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes (MIB48)

    NICE has developed a medtech innovation briefing (MIB) on the CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes .

  6. Smart Peak Flow for monitoring asthma (MIB282)

    NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .

  7. Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: late-stage assessment (HTG757)

    Late stage assessment (LSA) guidance on transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis.

  8. Long‑term consequences of planning birth in different settings: What are the long‑term consequences for women and babies of planning birth in different settings?

    compared by accessing medical records and through qualitative interviews. Primary outcomes are long‑term physical morbidity, pain after...

  9. Bone mineral density (BMD) with FRAX:- What is the added prognostic value of BMD in the assessment of fracture risk with FRAX?

    scanning equipment. Currently, there are no definitive studies in primary or secondary care evaluating whether the addition...

  10. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued Reference number: GID-TA10764

  11. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

  12. The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns (MIB1)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Versajet II hydrosurgery system

  13. The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)

    NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .

  14. Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)

    Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.